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Abstract: Background. In an effort to optimize nonopera-
tive therapy in patients with locoregionally advanced head and
neck squamous cell cancer, the Southwest Oncology Group
conducted a phase II trial combining 3-drug taxane-containing
induction chemotherapy with accelerated fractionation/concom-
itant boost radiation and concomitant single-agent cisplatin.
Methods. Two induction courses using docetaxel (75 mg/
m2 on day 1), cisplatin (100 mg/m2 on day 1), and fluorouracil
(1000 mg/m2/day continuous intravenous infusion days 1–4)
were given, with an interval of 21 days. Patients who were
stable or responded to the chemotherapy received definitive
accelerated fractionation/concomitant boost radiation with
concurrent cisplatin (100 mg/m2) on days 1 and 22 of
radiation.
Results. There were 74 eligible and evaluable patients en-
rolled between March 1, 2003, and August 15, 2004; 52 (70%)
had stage IV disease. At least 1 grade 3-4 toxicity was experi-
enced by 63 patients (85%) during induction. A total of 61
patients completed induction and began concurrent chemora-
diotherapy; 50 (68%) completed all planned treatment. At least
1 grade 3-4 toxicity was noted in 53 of the 58 patients (91%)
evaluated for toxicity from concurrent chemoradiotherapy. Two
patients died during induction, and 2 during chemoradiation.
With a median follow-up of 36 months (range, 14–50), the 2-
year and 3-year overall survival estimates were 70% and 64%,
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with 2-year and 3-year progression-free survival estimates of
66% and 61%, respectively.
Conclusions. Three-drug induction chemotherapy followed
by accelerated fractionation/concomitant boost radiation and
concurrent cisplatin is toxic but feasible within a cooperative
group. In this patient cohort with advanced head and neck
squamous cell cancer, overall and progression-free survivals
were encouraging, justifying further study of this
approach. VC 2009 Wiley Periodicals, Inc. Head Neck 32:
221–228, 2010
Keywords: chemotherapy; radiation; chemoradiotherapy;
induction; concomitant
Multiple studies of both single-agent and com-
bination chemotherapy administered with con-
comitant definitive radiation have now been
reported and have demonstrated a clear survival
and locoregional control benefit when compared
with radiation therapy alone.1 The best studied
concurrent chemoradiotherapy regimen is radia-
tion and single-agent cisplatin, which has been
well established as a standard of care in the
management of patients with unresectable head
and neck cancer,2 nasopharyngeal cancer,3 and
in postoperative patients with poor prognostic
features.4–6 It has also been proven to be the
most successful strategy for nonoperative larynx
preservation.7 These conclusions have been con-
firmed and strengthened by the results of the
large meta-analysis of chemotherapy on head
and neck cancer (MACH-NC), which reported a
5-year 8% overall survival benefit (p < .0001)
with concurrent chemoradiotherapy regimens
when compared with radiotherapy alone.8,9
Along with the improved survival and locore-
gional control that has resulted from these
aggressive concomitant treatment schedules has
been an apparent shift in the pattern of treat-
ment failure. Historically, locoregional disease
control has been the most important concern in
disease management. Distant metastases were a
relatively uncommon event. Recently, several
single-institution phase II trials of aggressive
concurrent chemoradiotherapy and altered frac-
tionation radiation have reported locoregional
control rates in excess of 90%, with distant me-
tastases representing the most frequent cause of
treatment failure.10,11 This observation has sug-
gested a possible role for additional systemic
chemotherapy in an effort to improve overall
treatment success by decreasing this incidence
of distant recurrence.12,13 Given the difficulties
associated with the administration of adjuvant
chemotherapy after completion of definitive
chemoradiotherapy, re-exploration of the use of
induction therapy would seem to be reasonable.
Induction therapy is hardly a new concept in
the treatment of head and neck cancer. A large
number of phase III studies have been con-
ducted comparing induction chemotherapy fol-
lowed by definitive surgery and/or radiation to
definitive management alone. Response rates as
high as 90% using well-established treatment
regimens have been reported.13 Although indi-
vidual studies have failed to demonstrate any
consistent improvement in locoregional control
or survival, meta-analysis has been able to iden-
tify a small survival benefit (hazard ratio 0.88,
95% CI: 0.79–0.97) for induction regimens con-
taining fluorouracil and a platin, the most
widely tested chemotherapy combination used
in this setting.8 In several of these induction
chemotherapy trials it was also noted that dis-
tant metastases were reduced in those patients
who received chemotherapy.14–16 Thus, the argu-
ment can be made that the sequential use of
aggressive multiagent induction therapy fol-
lowed by optimal definitive chemoradiotherapy
may successfully improve both locoregional and
distant control and further improve overall
survival.13,17
Recent work has produced evidence that the
incorporation of a taxane, either paclitaxel or
docetaxel, into the well-tested fluorouracil and
cisplatin combination can produce additional
benefit. Hitt et al,18 Vermorken et al,19 and Pos-
ner et al20 have reported results from 3 separate
phase III studies comparing induction fluoroura-
cil and cisplatin with induction fluorouracil, cis-
platin, and a taxane followed by definitive
therapy. Improvements in overall response rate,
complete response rate, organ preservation, and
survival were reported. Thus, a 3-drug combina-
tion of fluorouracil, cisplatin, and either pacli-
taxel or docetaxel can be considered to be the
most effective induction chemotherapy combina-
tion for this disease, and, as such, would be the
appropriate choice for this kind of sequential
treatment regimen.
The optimal radiation therapy fractionation
schedule has also been an unresolved question
for many years. The results from a large Radia-
tion Therapy Oncology Group trial (RTOG 9003)
and other phase III studies appear to demon-
strate a locoregional control benefit from altered
fractionation treatment schedules when com-
pared with conventional once-daily treatment.21
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Meta-analysis has confirmed this conclusion.22
Although the best altered fractionation
approach is yet undefined, RTOG 9003 sug-
gested a benefit from the accelerated fractiona-
tion/concomitant boost treatment schedule.
The hypothesis behind this phase II South-
west Oncology Group trial was that optimal
nonoperative therapy should address both
locoregional control and distant metastases and
should therefore sequentially employ the most
effective multimodality components available to
achieve each of these ends. An induction taxane,
fluorouracil, and cisplatin combination chemo-
therapy regimen was chosen followed by concur-
rent chemoradiotherapy using single-agent
cisplatin and altered fractionation radiation
therapy with the accelerated fractionation con-
comitant boost schedule. We chose to give only 2
cycles of induction chemotherapy, rather than
the 318,20 or 419 cycles used by previous investi-
gators, because of concern about the potential
for cumulative cisplatin neurotoxicity.
The objectives of this trial were to (1) assess
the overall survival in patients with advanced
head and neck squamous cell cancer treated
with this multimodality treatment regimen; (2)
estimate the clinical complete response rate af-
ter both induction therapy and concomitant che-
moradiotherapy; and (3) evaluate the toxicities
of induction chemotherapy and of this entire
multimodality treatment approach.
PATIENTS AND METHODS
Enrollment on this trial required the diagnosis of
a previously untreated stage III or IV (M0) head
and neck squamous cell cancer with an identified
primary site excluding the lip, nasopharynx, par-
anasal sinus, or salivary gland. Patients were eli-
gible if deemed appropriate for radiation therapy
with curative intent. A Zubrod performance sta-
tus of 0 or 1; adequate hematologic, renal, and he-
patic function; and a chest radiograph that did
not demonstrate any metastatic disease were
also required. Pretreatment evaluation by radia-
tion oncology, medical oncology, head and neck
surgery and dentistry, and documentation of dis-
ease extent by either CT or MRI were mandated.
Positron emission tomography scans were not
routinely requested for this study. An examina-
tion under anesthesia was required if deemed
necessary by the head and neck surgeon. Those
patients with pre-existing peripheral neuropathy
were excluded. Similarly, patients with any prior
malignancy were also ineligible for this trial,
excluding those with adequately treated basal
cell or squamous cell skin cancer, in situ cervical
cancer, or adequately treated stage I or II cancer
in remission for 5 years.
This study was conducted under the auspices
of the Southwest Oncology Group and approved
by the local institutional review boards of all
participating institutions. Written informed con-
sent, in accordance with institutional and fed-
eral guidelines, was required from all patients
before entering this protocol.
The treatment schema is depicted in Figure
1. Treatment included induction chemotherapy
followed by concurrent chemoradiotherapy.
Induction chemotherapy utilized a 3-drug combi-
nation of intravenous docetaxel 75 mg/m2 on
day 1, cisplatin 100 mg/m2 on day 1, and fluo-
rouracil 1000 mg/m2/day as a continuous 24-
FIGURE 1. S0216: treatment schema.
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hour intravenous infusion for 4 days beginning
on day 1. Two courses of this treatment regimen
were given with an interval of 21 days. Patients
received prophylactic ciprofloxacin for 10 days
after chemotherapy administration and stand-
ard antiemetics, hydration, and diuresis.
Three weeks after completion of the second
cycle of induction chemotherapy, a response
assessment was made using the same technique
performed to document baseline disease. An ex-
amination under anesthesia was not required at
this time. Patients with stable or responding tu-
mor were then treated with concurrent chemo-
radiotherapy. Patients with progressive disease
during or after induction chemotherapy were
considered for surgical resection, if possible,
with appropriate postoperative radiation ther-
apy. If surgery was not possible in these
patients, chemoradiotherapy was administered
as per the protocol.
Radiotherapy consisted of the RTOG-acceler-
ated fractionation, concomitant boost schedule.
Patients were given 54 Gy in 30 daily fractions,
5 days per week at 180 cGy per fraction to the
total treatment volume. Concomitant with the
last 12 treatments, a boost volume was treated
with 18 Gy at a rate of 150 cGy per day. The
total volume included the primary tumor, neck
nodes, and all areas at risk for microscopic dis-
ease. Boost volume included the primary tumor
with a 1.5-cm margin, and any clinically
enlarged lymph nodes. A minimum of 6 hours
was required between the radiation administra-
tion to the total volume and to the boost volume
on the last 12 concomitant treatment days. Only
megavoltage equipment was allowed, and the
use of intensity-modulated radiation therapy
was not permitted on this study. Maximum dose
to the spinal cord was 45 Gy. Two doses of con-
current cisplatin 100 mg/m2 were given on days
1 and 22 of the radiation therapy along with
standard hydration and antiemetic therapy.
Between 8 and 12 weeks after the completion
of concomitant chemoradiotherapy, all patients
underwent a comprehensive clinical and radiolog-
ical assessment of response. The response assess-
ment was again based on the same technique
used at baseline. Patients who achieved a com-
plete response to concomitant chemoradiotherapy
were followed up for disease recurrence. Surgical
resection was considered after concomitant che-
moradiotherapy for those patients with histologi-
cally confirmed residual or recurrent disease at
the primary site. Neck dissection was considered
for all patients with clinical evidence of residual
neck node disease after chemoradiotherapy and
for patients with N2 or greater disease at presen-
tation irrespective of their clinical response.
Statistical Considerations. Based on the results
reported from RTOG 9003,21 it was assumed
that this treatment approach would not warrant
further study if the true 2-year overall survival
probability was 45% or less. If, however, the
true 2-year overall survival probability was at
least 61%, it would be of considerable interest in
the treatment of advanced head and neck can-
cer. With 60 eligible patients enrolled over 2
years and an additional 2 years of follow-up, the
power of a 1-sided log-rank test to detect an
increase in the 2-year survival from 45% to 61%
was 83% with an alpha of 0.05. An observed 2-
year survival probability of 58% or greater
would be considered as sufficient evidence to
justify further study of this treatment approach,
provided other factors such as progression-free
survival and toxicity also appeared favorable.
Response at the primary, in the neck, and
overall were each documented separately after
the completion of induction chemotherapy and
again after the completion of concurrent chemo-
radiotherapy. Sixty patients would be sufficient
to estimate each of these clinically complete
response rates to within 13% (95% CI). Sixty
patients would also be sufficient to estimate any
toxicity rate to within 13% (95% CI). Any toxic-
ity with at least a 5% chance of occurring was
likely to be seen at least once with 95%
probability.
Overall survival and progression-free sur-
vival estimates were calculated using the
method of Kaplan–Meier.23 The survival times
were calculated from the date of registration (no
more than 5 working days before the initiation
of induction chemotherapy) to the date of death
due to any cause. Patients last known to be
alive were censored at date of last contact. Pro-
gression-free survival times were calculated
from the date of registration to the date of first
documentation of progression (as defined by the
Response Evaluation Criteria in Solid Tumors
[RECIST] group), symptomatic deterioration
(global deterioration of health status requiring
discontinuation of treatment), or death due to
any cause. Patients who had not been observed
experiencing 1 of these events were censored at
the date of last contact.
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RESULTS
Between March 1, 2003, and August 15, 2004,
76 patients were enrolled in this clinical trial.
Two of these patients were deemed ineligible
because of the presence of metastatic disease at
entry, leaving 74 eligible and evaluable patients.
Forty-one of these patients were from 7 member
institutions of the Southwest Oncology Group.
Thirty-five of these patients were from 15 differ-
ent community affiliates of the Southwest On-
cology Group member institutions.
The patient characteristics are shown in Ta-
ble 1. Tumor and nodal disease extent based on
the 6th edition of the American Joint Committee
Cancer Staging Manual24 is shown in Table 2.
Overall, 70% of patients had stage IV disease,
15% with stage IVB tumors.
Patient accounting is detailed in Figure 2. Of
the 74 eligible patients who began induction
chemotherapy, 68 (92%) completed it. Sixty-one
of these 68 patients (or 82% of the original 74)
began concurrent chemoradiotherapy, all but 1
within 3 to 4 weeks of induction chemotherapy
as specified by the protocol. Fifty patients (or
68% of the original 74) finished both induction
cycles and all planned radiation. Both concur-
rent chemotherapy doses could be given to 45 of
these 50 patients. The reasons for premature
treatment discontinuation are indicated in the
figure and were related to the treatment toxicity
in 14 patients. Five patients were taken off
study because of progressive disease during
therapy. No statistically significant differences
in patient or tumor characteristics could be
identified between the 50 patients who com-
pleted their treatment and the 24 who did not.
Table 3 details the acute toxicity experienced
by the 74 patients who underwent induction
therapy. Grade 3-4 neutropenia was experienced
by 59% of patients, and 18% required hospitali-
zation for neutropenic fever. There were 2 toxic
deaths, 1 due to febrile neutropenia and 1 from
a cardiac cause. Overall, at least 1 grade 3 or
greater toxicity occurred in 85% of patients. Ta-
ble 3 also details the acute toxicity during
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Table 2. Tumor (T) and nodal (N) distribution (n ¼ 74).
N
classification
No. of patients by T
classification
Total no.
of patientsT1 T2 T3 T4a T4b
N0 7 2 0 9
N1 2 4 9 3 0 18
N2a 0 2 4 0 0 6
N2b 1 3 7 5 1 17
N2c 2 4 2 6 3 17
N3 3 1 2 1 0 7
Total 8 14 31 17 4 74
FIGURE 2. S0216: patient accounting.
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concurrent chemoradiotherapy in the 58
patients for whom data are available. Grade 3-4
mucositis was experienced by 48% of patients
and grade 3-4 neutropenia by 31%. Hospitaliza-
tion for neutropenic fever was required in 5% of
patients. There were 2 additional toxic deaths
during concurrent chemoradiotherapy, 1 from
febrile neutropenia and 1 from a cardiac cause.
Overall, 91% of patients experienced at least 1
grade 3 or greater toxicity during concurrent
chemoradiotherapy.
After induction therapy, an unconfirmed clin-
ically complete response was identified at the
primary site in 12 patients (16%), and in the
neck in 8 of the 65 patients (12%) with lymph
node involvement at baseline. An overall com-
plete response was documented in 5 patients
(7%). After concurrent chemoradiotherapy, a pri-
mary site complete response was noted in 25
(34%) patients, a complete response in the neck
was noted in 20 of 65 patients (31%) with nodal
involvement at baseline, and an overall com-
plete response was documented in 21 patients
(28%).
With a median follow-up of 36 months
(range, 14–50), the 2-year and 3-year progres-
sion-free survival estimates were 66% (95% CI:
55%–77%) and 61% (95% CI: 50%–73%), respec-
tively (Figure 3A). The 2-year and 3-year overall
survival estimates were 70% (95% CI: 60%–
81%) and 64% (95% CI: 52%–75%), respectively
(Figure 3B).
The analysis of patterns of failure is dis-
played in Table 4, but is not terribly revealing.
Disease progression or death occurred in 29
patients, 12 of whom died before disease pro-
gression could be documented. Second, primary
malignancies were identified in 4 patients: 2
with lung cancer, and 1 each with kidney and
colon cancer. All 4 patients were alive, without
evidence of their head and neck cancer, at the
time of this analysis.
Table 3. Toxicity grade 3.
Toxicity No. (%)
Induction chemotherapy (n ¼ 74)
Nausea, vomiting 19 (26)
Anorexia 8 (11)
Dehydration 11 (15)
Renal dysfunction 1 (1)
Mucositis 15 (20)
Neutropenia 44 (59)
With fever 13 (18)
Thrombocytopenia 5 (7)
Anemia 3 (4)
Toxic death during induction 2 (3)
Total with grade 3 toxicity 63 (85)
Concurrent chemoradiotherapy (N ¼ 58)
Nausea, vomiting 14 (24)
Anorexia 10 (17)
Dehydration 13 (22)
Renal dysfunction 5 (9)
Mucositis 28 (48)
Neutropenia 18 (31)
With fever 3 (5)
Thrombocytopenia 4 (7)
Anemia 5 (9)
Toxic death during chemoradiotherapy 2 (3)
Total with grade 3 toxicity 53 (91)
FIGURE 3. Progression-free (A) and overall (B) survival.
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DISCUSSION
In this cohort of patients with locoregionally
advanced squamous cell head and neck cancer,
this aggressive sequential treatment schedule
produced very encouraging 2-year progression-
free and overall survival rates. It should be
pointed out that a significant fraction of these
patients were from community-based oncology
affiliates of larger Southwest Oncology Group
member institutions, suggesting that this kind
of intensive treatment can be successfully
administered in the community.
At first glance, the overall complete response
rates of only 7% after 3-drug induction chemo-
therapy and 28% after concurrent chemoradio-
therapy seem disappointingly low, particularly
in a patient population being treated with cura-
tive intent. These results must be viewed with
caution, however, given the constraints of the
RECIST definition of a complete response. Fur-
thermore, residual radiographic abnormalities of
measurable lesions are frequently found after
chemotherapy and radiation and often do not
reflect residual cancer. Many of the patients
who did not achieve a formal complete response
remain alive and progression free, years after
completing treatment. In patients with this dis-
ease, the progression-free and overall survivals
are far better measures of treatment effect than
the complete response rate.
It must be stressed, however, that this is a
very toxic treatment regimen. More than 90% of
patients experienced at least 1 grade 3 or
greater toxicity, and many patients experienced
multiple toxicities. Four of the 74 patients (5%)
in this trial died from treatment-related compli-
cations. Although this toxicity is in keeping
with that observed in other similar multimodal-
ity treatment trials, it clearly strains the limita-
tions of acceptability for any clinical treatment
program. This toxicity and the potential for
toxic death underscore how important it is that
both treating physician and institution are fa-
miliar with this approach to head and neck can-
cer, and with the necessary supportive care.
The treatment could be completed and there-
fore proved feasible in 68% of patients in this
study. It is important, however, to examine this
notion of feasibility within the context of other
recent trials in this disease, particularly those
conducted in a cooperative group setting. Feasi-
bility has been reported from similar cooperative
group studies of chemotherapy and radiation for
squamous cell head and neck cancer. In studies
using radiation and single-agent cisplatin, even
when that radiation is administered using an
altered fractionation schedule, the feasibility
has, in general, ranged from 83% to 85%.2,4,25
When treatment becomes more complex, how-
ever, utilizing adjuvant chemotherapy,3 concur-
rent multiagent chemotherapy,2 or sequential
treatment regimens similar to this trial,20 the
feasibility drops to between 55% and 73%,
results more in keeping with this study. Clearly,
there is a trade-off between the aggressiveness
and complexity of a treatment regimen and the
likelihood that it can be completed. The obvious
concern is that these more aggressive and more
complex treatment regimens may ultimately not
improve outcome if the treatment cannot be
completed.
It should be noted that 30% of the patients
in this trial had stage III tumors. These patients
may have been successfully treated with less in-
tensive or less complicated regimens. It is of
critical importance that we continue to attempt
to identify selection factors that might better
suggest which patients require the most aggres-
sive therapies and which patients should be
treated less intensively, or, alternatively, with
surgery. The University of Michigan group has,
for example, suggested that in laryngeal cancer,
failure to respond to a single course of induction
chemotherapy may identify a patient less likely
to do well with chemoradiotherapy who might
be better treated surgically.26
This phase II trial reports the feasibility and
toxicity of this kind of sequential treatment
approach and suggests that there is considerable
efficacy in this patient population. This kind of
sequential treatment schedule, however, remains
investigational. Although theoretically attrac-
tive, the value of induction chemotherapy prior to
definitive concurrent chemoradiotherapy has not
been firmly established. We await the results of
the phase III randomized trials currently being
conducted that address this question.13
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